Beta-blocker-associated hypoglycaemia: New insights from a real-world pharmacovigilance study.
Carla CarnovaleMichele GringeriVera BattiniGiulia MosiniElena InvernizziFaizan MazharFrancesco BergamaschiMara FumagalliGianvincenzo ZuccottiEmilio ClementiSonia RadiceValentina FabianoPublished in: British journal of clinical pharmacology (2021)
Nadolol appears to be the β-blocker significantly most associated with hypoglycaemia and children represent the most susceptible sample. Furthermore, long half-life and nonselective β-blockers seem to increase the risk for its occurrence.